<p>随着美国市场进入假期缩短的一周，主要股指收盘下跌，科技股领跌，因市场对科技行业资本支出的担忧加剧。在这种环境下，识别高增长的科技股需要对市场动态有敏锐的理解，并能够驾驭可能影响小型公司的经济指标。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 72 只股票完整列表。</p>
<p>下面我们展示了一些经过筛选的股票。</p>
<h2>MongoDB (MDB)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MongoDB, Inc. 在全球提供通用数据库平台，市值为 344.4 亿美元。</p>
<p><strong>运营：</strong> 公司的主要收入来源于其数据处理部门，产生了 23.2 亿美元的收入。专注于提供通用数据库平台支持其全球运营。</p>
<p>在动态的科技环境中，MongoDB 展现了强大的财务灵活性和战略前瞻性。其年收入增长率为 15.7%，超过美国市场的 10.7%，公司正处于明确的上升轨道。最近的股票回购，包括 513,620 股，金额为 1.5101 亿美元，彰显了对其财务健康和未来前景的信心。此外，MongoDB 对创新的承诺在其研发支出趋势中显而易见，这对在竞争激烈的科技行业中维持长期增长至关重要。这种对研究的关注不仅推动了产品的提升，也使 MongoDB 在高风险的人工智能和云领域中占据了良好的位置，继续扩大其影响力。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 MongoDB 的动态。</li>
<li>了解 MongoDB 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="1046" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 MDB 收入和支出细分</p>
<h2>Intapp (INTA)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Intapp, Inc. 通过其子公司 Integration Appliance, Inc. 在美国、英国及国际市场提供人工智能驱动的解决方案，市值约为 38.9 亿美元。</p>
<p><strong>运营：</strong> Integration Appliance, Inc. 是 Intapp 的子公司，主要通过其软件和编程部门产生收入，收入为 5.2434 亿美元。</p>
<p>Intapp 在竞争激烈的科技环境中展现了韧性和适应能力。尽管在 2026 年第一季度报告了 1435 万美元的净亏损，较去年同期的 452 万美元有所增加，但公司预计年收入增长 12%，略高于美国市场平均水平 10.7%。这一预测与其战略举措如 Intapp Collaboration 相一致，该举措与 Microsoft 365 无缝集成，以增强客户参与度和提高 Ostberg Sinclair &amp; Co.等公司的运营效率。此外，Intapp 最近以约 5000 万美元回购超过一百万股股票，显示出对其未来发展轨迹的强烈信心，以及在持续创新和市场扩张中的对股东价值的承诺。</p>
<ul>
<li>点击这里深入了解 Intapp 的完整分析健康报告。</li>
<li>查看我们的历史表现报告，以获取 Intapp 过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 INTA 盈利和收入增长</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因治疗，市值为 73.6 亿美元。</p>
<p><strong>运营：</strong> Krystal Biotech 通过商业化针对重大未满足医疗需求疾病的基因治疗产生收入，在该领域报告了 3.7316 亿美元的收入。公司在生物技术行业内运营，专注于创新和开发，以应对美国的重大健康挑战。</p>
<p>Krystal Biotech 最近的成就凸显了其在高增长生物技术领域的战略定位，第三季度净收入从去年同期的 2718 万美元大幅增加至 7937 万美元，反映出令人印象深刻的年增长。公司的前瞻性举措体现在其获得 FDA 授予的 KB801 平台技术认证，增强了其在眼科领域的管道潜力。这与过去一年 279.8% 的盈利激增和预计年收入增长 26.1% 相一致，超过美国市场 10.7% 的预测。这些里程碑不仅突显了 Krystal 的创新优势，也预示着在行业进步中强劲的未来前景。</p>
<ul>
<li>在我们的健康报告中更深入地了解 Krystal Biotech 的潜力。</li>
<li>通过我们的历史报告获取 Krystal Biotech 过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS 截至 2025 年 12 月的收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>在这里探索我们美国高增长科技和人工智能股票筛选器中的 72 个名称。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时了解您股票的任何重要更新。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
<h2>准备好尝试不同的方法吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

新美亚电子

PLTR

<p>随着美国市场迎来假期缩短的一周，主要股指出现下跌，尤其是科技板块因对资本支出的担忧而受到影响。识别高增长的科技股票至关重要，其中 Marker Therapeutics、Sanmina 和 Palantir Technologies 等公司显示出显著的收入和盈利增长。MongoDB 和 Intapp 因其韧性和战略举措而受到关注，而 Krystal Biotech 在生物科技领域表现强劲。报告强调了理解市场动态和经济指标在投资高增长科技股票中的重要性</p>

<p>As the United States market enters a holiday-shortened week, major stock indexes have closed lower, with technology shares leading declines amid broader concerns about capital expenditures in the tech sector. In this environment, identifying high-growth tech stocks requires a keen understanding of market dynamics and an ability to navigate economic indicators that may impact small-cap companies.</p>
<div class="lb-trans"><p>随着美国市场进入假期缩短的一周，主要股指收盘下跌，科技股领跌，因市场对科技行业资本支出的担忧加剧。在这种环境下，识别高增长的科技股需要对市场动态有敏锐的理解，并能够驾驭可能影响小型公司的经济指标。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 72 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 72 只股票完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我们展示了一些经过筛选的股票。</p>
</div><h2>MongoDB (MDB)</h2>
<div class="lb-trans"><h2>MongoDB (MDB)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MongoDB, Inc. offers a general-purpose database platform globally and has a market capitalization of $34.44 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MongoDB, Inc. 在全球提供通用数据库平台，市值为 344.4 亿美元。</p>
</div><p><strong>Operations:</strong> The company's primary revenue stream is from its data processing segment, which generated $2.32 billion. The focus on providing a general-purpose database platform supports its global operations.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的主要收入来源于其数据处理部门，产生了 23.2 亿美元的收入。专注于提供通用数据库平台支持其全球运营。</p>
</div><p>Amidst a dynamic tech landscape, MongoDB has demonstrated robust financial agility and strategic foresight. With a notable 15.7% annual revenue growth outpacing the US market's 10.7%, the company is on a clear upward trajectory. Recent share buybacks, including 513,620 shares for $151.01 million, underscore confidence in its financial health and future prospects. Additionally, MongoDB's commitment to innovation is evident from its R&amp;D spending trends which are crucial for sustaining long-term growth in the competitive tech sector. This focus on research not only fuels product enhancement but also positions MongoDB well within the high-stakes AI and cloud domains where it continues to expand its footprint.</p>
<div class="lb-trans"><p>在动态的科技环境中，MongoDB 展现了强大的财务灵活性和战略前瞻性。其年收入增长率为 15.7%，超过美国市场的 10.7%，公司正处于明确的上升轨道。最近的股票回购，包括 513,620 股，金额为 1.5101 亿美元，彰显了对其财务健康和未来前景的信心。此外，MongoDB 对创新的承诺在其研发支出趋势中显而易见，这对在竞争激烈的科技行业中维持长期增长至关重要。这种对研究的关注不仅推动了产品的提升，也使 MongoDB 在高风险的人工智能和云领域中占据了良好的位置，继续扩大其影响力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of MongoDB.</li>
<li>Learn about MongoDB's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 MongoDB 的动态。</li>
<li>了解 MongoDB 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown"/></p>
<p>MDB Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 MDB 收入和支出细分</p>
</div><h2>Intapp (INTA)</h2>
<div class="lb-trans"><h2>Intapp (INTA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Intapp, Inc., through its subsidiary Integration Appliance, Inc., delivers AI-powered solutions across the United States, the United Kingdom, and internationally with a market cap of approximately $3.89 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Intapp, Inc. 通过其子公司 Integration Appliance, Inc. 在美国、英国及国际市场提供人工智能驱动的解决方案，市值约为 38.9 亿美元。</p>
</div><p><strong>Operations:</strong> Integration Appliance, Inc., a subsidiary of Intapp, generates revenue primarily through its software and programming segment, which accounts for $524.34 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Integration Appliance, Inc. 是 Intapp 的子公司，主要通过其软件和编程部门产生收入，收入为 5.2434 亿美元。</p>
</div><p>Intapp, navigating the competitive tech landscape, has shown resilience and adaptability. Despite reporting a net loss of $14.35 million in Q1 2026, an increase from the previous year's $4.52 million, the company is poised for recovery with projected annual revenue growth of 12%, slightly above the US market average of 10.7%. This forecast aligns with its strategic initiatives like Intapp Collaboration which integrates seamlessly with Microsoft 365 to enhance client engagement and operational efficiency for firms like Ostberg Sinclair &amp; Co. Moreover, Intapp's recent repurchase of over a million shares for approximately $50 million signals strong confidence in its future trajectory and commitment to shareholder value amidst ongoing innovations and market expansions.</p>
<div class="lb-trans"><p>Intapp 在竞争激烈的科技环境中展现了韧性和适应能力。尽管在 2026 年第一季度报告了 1435 万美元的净亏损，较去年同期的 452 万美元有所增加，但公司预计年收入增长 12%，略高于美国市场平均水平 10.7%。这一预测与其战略举措如 Intapp Collaboration 相一致，该举措与 Microsoft 365 无缝集成，以增强客户参与度和提高 Ostberg Sinclair &amp; Co.等公司的运营效率。此外，Intapp 最近以约 5000 万美元回购超过一百万股股票，显示出对其未来发展轨迹的强烈信心，以及在持续创新和市场扩张中的对股东价值的承诺。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Intapp.</li>
<li>Review our historical performance report to gain insights into Intapp's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Intapp 的完整分析健康报告。</li>
<li>查看我们的历史表现报告，以获取 Intapp 过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth"/></p>
<p>INTA Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 INTA 盈利和收入增长</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $7.36 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因治疗，市值为 73.6 亿美元。</p>
</div><p><strong>Operations:</strong> Krystal Biotech generates revenue by commercializing genetic medicines aimed at treating diseases with significant unmet medical needs, reporting $373.16 million in this segment. The company operates within the biotechnology sector, focusing on innovation and development to address critical health challenges in the U.S.</p>
<div class="lb-trans"><p><strong>运营：</strong> Krystal Biotech 通过商业化针对重大未满足医疗需求疾病的基因治疗产生收入，在该领域报告了 3.7316 亿美元的收入。公司在生物技术行业内运营，专注于创新和开发，以应对美国的重大健康挑战。</p>
</div><p>Krystal Biotech's recent achievements underscore its strategic positioning in the high-growth biotech sector, marked by a robust increase in net income to $79.37 million for Q3 2025 from $27.18 million the previous year, reflecting an impressive annual growth. The company's forward-looking initiatives are evident from its FDA-granted platform technology designation for KB801, enhancing its pipeline potential in ophthalmology. This aligns with a significant 279.8% earnings surge over the past year and an expected revenue growth of 26.1% per annum, surpassing the US market forecast of 10.7%. These milestones not only highlight Krystal's innovative edge but also signal strong future prospects amid industry advancements.</p>
<div class="lb-trans"><p>Krystal Biotech 最近的成就凸显了其在高增长生物技术领域的战略定位，第三季度净收入从去年同期的 2718 万美元大幅增加至 7937 万美元，反映出令人印象深刻的年增长。公司的前瞻性举措体现在其获得 FDA 授予的 KB801 平台技术认证，增强了其在眼科领域的管道潜力。这与过去一年 279.8% 的盈利激增和预计年收入增长 26.1% 相一致，超过美国市场 10.7% 的预测。这些里程碑不仅突显了 Krystal 的创新优势，也预示着在行业进步中强劲的未来前景。</p>
</div><ul>
<li>Take a closer look at Krystal Biotech's potential here in our health report.</li>
<li>Gain insights into Krystal Biotech's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解 Krystal Biotech 的潜力。</li>
<li>通过我们的历史报告获取 Krystal Biotech 过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>KRYS 截至 2025 年 12 月的收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Explore the 72 names from our US High Growth Tech and AI Stocks screener here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们美国高增长科技和人工智能股票筛选器中的 72 个名称。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时了解您股票的任何重要更新。</li>
<li>通过使用 Simply Wall St 加入聪明投资者的社区。它是免费的，并提供全球市场的专家级分析。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好尝试不同的方法吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随处可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Exploring High Growth Tech Stocks In The US For December 2025

- 美国主要股指下跌，科技股因资本支出担忧领跌。  
- 前十大高增长科技公司包括 Marker Therapeutics 和 Palantir Technologies 等。  
- MongoDB 及 Intapp 显示出强劲的财务成长潜力，尤其在研发和市场扩展方面。

探索 2025 年 12 月美国高增长科技股票